The role of urine neutrophil gelatinase – associated lipocalin (NGAL) in acute heart failure in patients with ST – elevation myocardial infarction

BMC Cardiovascular Disorders

Andreja Sinkovič¹  Maksimiljan Gorenjak²  Simona Kirbiš¹ 

[1] Department of intensive care unit, University Clinical Center Maribor, Ljubljanska 5, Maribor 2000, SI, Slovenia;Department of laboratory diagnostics, University Clinical Center Maribor, Maribor, Slovenia

关键词: Acute kidney injury;    Myocardial infarction;    Heart failure;    Neutrophil gelatinase-associated lipocalin - NGAL;   

Others  :  1212265
DOI  :  10.1186/s12872-015-0054-9

 received in 2015-02-23, accepted in 2015-06-01,  发布年份 2015

【 摘 要 】

Background

Neutrophil gelatinase-associated lipocalin (NGAL) is a novel early marker of acute kidney injury for which has been shown that it can also be released from the injured myocardium. Our aim was to correlate urine NGAL with markers of in-hospital heart failure in patients with acute ST-elevation myocardial infarction (STEMI).

Methods

We prospectively included 61 consecutive STEMI patients after primary percutaneous coronary intervention and estimated admission and in-hospital urine NGAL, serum creatinine, troponin I, leucocytes, CRP, N-terminal pro brain natriuretic peptide (NT-proBNP) levels and ejection fraction by echocardiography. Urine NGAL levels were compared between patients with and without HF defined as serum NT-proBNP > 400 pmol/l and were correlated to markers of heart failure, inflammations and of kidney function.

Results

Urine NGAL levels and CRP was significantly higher in participants with heart failure compared to those with NT-proBNP below 400 pmol/l. Urine NGAL level of 50 ng/ml had 90 % specificity for HF, the sensitivity was low at 25 %. Comparison of participants with NGAL levels < 50 ng/ml and ≥ 50 ng/ml at admission and after 12 h revealed a significant difference in NT-proBNP levels, left ventricle ejection fraction, markers of inflammation and of kidney function. Urine NGAL level was independently associated with NT-proBNP level.

Conclusions

The level of urine NGAL early after myocardial infarction is associated with NT-proBNP concentration and even NGAL levels below 137 ng/ml, the usually reported normal cut-off value, had high specificity for HF in our sample.

【 授权许可】

   
2015 Simona et al.

【 图 表 】

Fig. 1.

Fig. 2.

Fig. 3.

【 参考文献 】

• [1]Elneihoum AM, Falke P, Hedblad B, Lindgarde F, Ohlsson K: Leukocyte activation in atherosclerosis: correlation with risk factors. Atherosclerosis 1997, 131:79-84.
• [2]Falke P, Elneihoum AM, Ohlsson K: Leukocyte activation: relation to cardiovascular mortality after cerebrovascular ischemia. Cerebrovasc Dis 2000, 10:97-101.
• [3]Hochman JS: Cardiogenic shock complicating acute myocardial infarction: expanding the paradigm. Circulation 2003, 107:2998-3002.
• [4]Reynolds HR, Hochman JS: Cardiogenic shock: current concepts and improving outcomes. Circulation 2008, 117:686-97.
• [5]Kirbis S, Breskvar UD, Sabovic M, Zupan I, Sinkovic A: Inflammation markers in patients with coronary artery disease – comparison of intracoronary and systemic levels. Wien Klin Wochenschr 2010, 122:31-4.
• [6]Kjeldsen L, Bainton DF, Sengelov H, Borregaard N: Identification of neutrophil gelatinase-associated lipocalin as a novel matrix protein of specific granules in human neutrophils. Blood 1994, 83:799-807.
• [7]Kjeldsen L, Johnsen AH, Sengelov H, Borregaard N: Isolation and primary structure of NGAL, a novel protein associated with human neutrophil gelatinase. J Biol Chem 1993, 268:10425-32.
• [8]Ronco C: N-GAL: diagnosing AKI as soon as possible. Crit Care 2007, 11:173. BioMed Central Full Text
• [9]Malyszko J, Bachorzewska G, Malyszko JS, Pawlak K, Dobrzycki S: Serum neutrophil gelatinase-associated lipocalin as a marker of renal function in hypertensive and normotensive patients with coronary artery disease. Nephrology 2008, 13:153-6.
• [10]Vinten-Johansen J: Involvement of neutrophils in the pathogenesis of lethal myocardial reperfusion injury. Cardiovasc Res 2004, 61:481-97.
• [11]Tang WH, Brennan ML, Philip K, Tong W, Mann S, Van Lente F, et al.: Plasma myeloperoxidase levels in patients with chronic heart failure. Am J Cardiol 2006, 98:796-9.
• [12]Tang WH, Tong W, Troughton RW, Martin MG, Shrestha K, Borowski A, et al.: Prognostic value and echocardiographic determinants of plasma myeloperoxidase levels in chronic heart failure. J Am Coll Cardiol 2007, 49:2364-70.
• [13]Van de Werf F, Blomstrom-Lundqvist CB, Crea F, Falk V, Filippatos G, Fox K, et al.: Management of acute myocardial infarction in patients presenting with persistent ST-segment elevation-ESC guidelines. Eur Heart J 2008, 29:2909-45.
• [14]Wijns W, Kolh P, Danchin N, Di Mario C, Falk V, Folliguet T, et al.: Guidelines on myocardial revascularization. The task force on myocardial revascularization of the European society of cardiology (ESC) and the European association for cardio-thoracic surgery. Eur Heart J 2010, 31(20):2501-55.
• [15]Lang RM, Bierig M, Devereux RB, Flachskampf FA, Pelikka PA, Picard MH, et al.: Recommendations for chamber quantification: a report from the American society of echocardiography’s guidelines and standards committee and the chamber quantification writing group, developed in conjunction with the European association of echocardiography, a branch of the European society of cardiology. J Am Soc Echocardiogr 2005, 18:1440-63.
• [16]Dickstein K, Cohen-Solal A, Filippatos G, McMurray JJV, Ponikowski P, Poole-Wilson PA, et al.: ESC guidelines for the diagnosis and treatment of acute and chronic heart failure 2008. The task force for the diagnosis and treatment of acute and chronic heart failure 2008 of the European society of cardiology. Developed in collaboration with the Heart failure Association of the ESC (HFA) and endorsed by the European society of intensive care medicine (ESCIM). Eur J Heart Fail 2008, 10:933-89.
• [17]Palazzuoli A, Ruocco G, Beltrami M, Franci B, Pellegrini M, Lucani B, et al. Admission plasma neutrophil gelatinase-associated lipocalin (NGAL) predicts worsening renal function during hospitalization and post discharge outcome in patients with acute heart failure. Acute Card Care. 2014, (early Online).
• [18]Damman K, van Veldhuisen DJ, Navis G, Voors AA, Hillege HL: Urinary neutrophil gelatinase associated lipocalin (NGAL), a marker of tubular damage, is increased in patients with chronic heart failure. Eur J Heart Fail 2008, 10:997-1000.
• [19]Bolignano D, Basile G, Parisi P, Coppolino G, Nicocia G, Buemi M: Increased plasma neutrophil gelatinase-associated lipocalin levels predict mortality in elderly patients with chronic heart failure. Rejuvenation Res 2009, 12:7-14.
• [20]Van Deursen VM, Damman K, Voors AA, Van der Wal MH, Jaarsma T, Van Veldhuisen DJ, et al.: Prognostic value of plasma neutrophil gelatinase-associated lipocalin for mortality in patients with heart failure. Circ Heart Fail 2014, 7(1):35-42.
• [21]Yndestad A, Landro L, Ueland T, Dahl CP, Flo TH, Vinge LE, et al.: Increased systemic and myocardial expression of neutrophil gelatinase-associated lipocalin in clinical and experimental heart failure. Eur Heart J 2009, 30:1229-36.
• [22]Aghel A, Shrestha K, Mullens W, Borowski A, Tang WH: Serum neutrophil gelatinase-associater lipocalin (NGAL) in predicting worsening renal function in acute decompensated heart failure. J Card Fail 2010, 16:49-54.